Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. - Wikidata - wikimedia - TriplyDB

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

http://www.wikidata.org/entity/Q38329285

about

Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and Opportunities Epigenetic regulators and their impact on therapy in acute myeloid leukemia Recent progress toward epigenetic therapies: the example of mixed lineage leukemia Combined Overexpression of JARID2, PRDM14, ESRRB, and SALL4A Dramatically Improves Efficiency and Kinetics of Reprogramming to Induced Pluripotent Stem Cells.Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin.A microRNA encoded by Kaposi sarcoma-associated herpesvirus promotes B-cell expansion in vivo JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines.Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Digging deep into "dirty" drugs - modulation of the methylation machinery.Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5.JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.Recent advances in the ARID family: focusing on roles in human cancer.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Genetic and epigenetic alterations of myeloproliferative disorders.Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.Lessons from next-generation sequencing analysis in hematological malignancies.Genetic basis of MPN: Beyond JAK2-V617F.Chromatin modifiers and the promise of epigenetic therapy in acute leukemia The controversial role of the Polycomb group proteins in transcription and cancer: how much do we not understand Polycomb proteins?Polycomb group proteins--epigenetic repressors with emerging roles in melanocytes and melanoma.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Epigenetic modifiers in normal and malignant hematopoiesis.What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?Mutations and deletions of PRC2 in prostate cancer.JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes.Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner.miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow : Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Gr Clinical significance of genetic aberrations in secondary acute myeloid leukemia.

P2860

Q21261481-2AE52B65-20A7-41EB-AFAD-8725B1ECE20B Q26744506-25456B7F-A6B6-47BA-9DCE-E9979D4BE59E Q26765402-8CB75300-8C13-4C71-80F1-76356442E5CB Q26863577-24AACAB6-51B7-42A9-9BBC-FE9442166447 Q29465547-E2E9B5A9-408F-423C-9952-2136747F7F7E Q31019526-C801F463-6F02-4CDB-81C0-E54D8DA54742 Q33402522-BBBF0F57-F0D2-4D2E-BC7F-72131A3C272E Q33631109-AA07AB45-5450-4BFE-B908-147F75E51EEE Q34490029-6D86383C-919C-4079-9D85-B1B19CC11A2B Q34776014-507D109F-9252-485E-B42B-9C7F2A2F5DF2 Q35781605-7736BA5E-BEA9-49AA-99A3-F7489D4BD0EA Q36445523-3C0B5427-935A-4890-B1AE-A5E8F09E4331 Q36523796-61B07254-5330-4F2A-971C-5E290568F9F8 Q37362742-2A059191-7364-423F-BF26-41FFC8B3C4E3 Q37457852-ED1739F0-4D77-4D5C-914E-6D7DE376F4F7 Q37601383-464104EA-6F0E-48A4-81F7-F2B7882054E5 Q38014534-2929573E-96C5-458F-A30B-D49821D65A06 Q38018908-5D593B7E-B0CD-4AC0-8BF3-50551D694059 Q38066786-29E9DA14-9844-4A34-8028-27980F696B3F Q38097735-0F52C94D-C3C7-42DE-813B-72FAF83E1463 Q38123015-115F15E5-CDE5-44AA-A90F-18DE462FCE55 Q38159973-FEEC4FEA-C014-4BDC-9907-D439C3C684D3 Q38194444-08C2F7E9-0B90-472E-8403-E138E5F54EC9 Q38260253-BE8FD4E2-D4BE-4069-B515-D9C3BF4EE07A Q38283093-3DC18213-0F31-4BAA-A65D-9486757518E8 Q38415206-F28F6FE8-197F-4EDC-BBCC-8D4F90C318F3 Q38459868-03C28C47-8DC4-42A3-BE6F-6B754F3A055E Q38597994-7D094B4B-9A05-41A6-BB27-A47CDF2E07BF Q38783694-C914C542-CF1C-43AA-9B5A-2DCE225E3BC0 Q38879248-3C95D68D-6FB9-4E81-9877-99EAD31740C8 Q38906194-46B4E883-6167-4B95-B3EA-831FEA33B51B Q38946185-6194C6C3-EF31-40C8-AFAE-DB87ED6F7731 Q38961785-6365FD7F-4233-4087-84EF-787AB4C0F64B Q39482201-680DB7D7-EB28-43E4-ADF9-AD899B633D4D Q39883150-59246FD7-130D-4382-A3FB-368774E11AEC Q41418744-AD5043B6-8D3B-49B1-8DED-8007D71A3E76 Q41842355-48C749B2-13A6-4A7D-A1F4-DD389D3DC165 Q42082695-E85EA821-47C1-4233-8D50-C85945028F36 Q42645612-EEBCD3BA-9796-4990-99D4-0C5E6F252CC1 Q43405916-9591F51F-4C2A-4C48-9675-040F16DC363B

P2860

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

http://www.wikidata.org/entity/Q38329285

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

@en

type

label

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

@en

prefLabel

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

@en

P1433

Q38329285-F116DF8F-B8E9-4803-8EE3-09334AC06A35

P1476

Q38329285-E320AC5C-A629-445F-A65A-AAE1D60874BF

P2093

Q38329285-1FB858B5-84D5-49D9-807B-EA6414C1281E

Q38329285-26C621C3-FFF4-4533-A86F-C1667E28E569

Q38329285-27C85821-247C-4C44-80D9-EC4A8641E0A6

Q38329285-42957435-D182-462F-8889-45E0C20182B3

Q38329285-48C1CF1F-63A1-49D3-9BDC-D67F32BA70F3

Q38329285-525154C4-A321-4201-8B3D-B13220C55A7F

Q38329285-6AF20BF6-AD5F-44C1-A02B-41FDA6159DB1

Q38329285-6D9B9E0B-EA72-42B7-BB35-523CBCEABA48

Q38329285-A8F54D6D-B950-4934-83F5-06419C043FA3

Q38329285-AC0A2BC1-EFBA-4244-BA29-B065EEF7DF50

P2860

Q38329285-07B412E6-96C1-44D7-A8D1-9561C79B4EB8

Q38329285-0C1293D0-DAAB-49C4-B161-6CEE1A24BBBC

Q38329285-100F6F2E-9008-4C2B-B616-DCF1BB79406D

Q38329285-169C3C7F-35F2-4550-AD91-D0B510B02F0F

Q38329285-1E176BC7-CD29-4C9F-B648-A3928C8FC3BE

Q38329285-1E6A4C5B-0D18-4A16-BF46-E367EA6697C8

Q38329285-2D7FF43B-FF54-4405-9B54-1C17902687F5

Q38329285-2F04DF45-4CF0-4848-A4F6-00B02CA060C6

Q38329285-3B00D2EF-04C6-4B84-B69E-F0E85772885E

Q38329285-400AC2E4-D62C-47E1-B8BA-806C000D677E

P304

Q38329285-D22036D9-1451-42B1-B394-1F63E1A5360D

P31

Q38329285-F4C673A0-5D92-4B46-A67C-4796BF3058A7

P356

Q38329285-B6FCBAEE-D469-448A-AC51-3F78C47B433F

P433

Q38329285-E4DF9A3F-7B54-423C-BC8E-B490A900281F

P478

Q38329285-A894CE89-1516-495F-963B-6B31E5BE0D15

P50

Q38329285-24EF949B-BC9A-49DD-B041-C34F9A253269

Q38329285-301346CB-6D04-4E24-8D3C-4160AE928AEE

Q38329285-6F3B3362-7731-48C8-ABA0-C127F9F0A694

Q38329285-80283A40-44E7-4FB5-A135-6BF6900A2BC2

Q38329285-C0DDDE54-4DD3-470C-B7FD-0BC8DBE46F3B

Q38329285-D8577539-0B9B-4A03-83AE-CDEAF433B174

P577

Q38329285-CE507E1D-2236-4E22-9005-8A8E1F8BFDA5

P5875

Q38329285-ED933244-BA85-45D4-A7A1-40B1D807B141

P698

Q38329285-30DD0D22-09DF-47D9-955E-3451E56FB393

P921

Q38329285-6D74BAE7-436C-43C9-90A1-F2730AB81877

P356

P1433

American Journal of Hematology

P1476

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies

@en

P2093

Alessandro M Vannucchi

http://www.w3.org/2001/XMLSchema#string

Ana Puda

http://www.w3.org/2001/XMLSchema#string

Bettina Gisslinger

http://www.w3.org/2001/XMLSchema#string

Chiara Elena

http://www.w3.org/2001/XMLSchema#string

Elisa Rumi

http://www.w3.org/2001/XMLSchema#string

Heinz Gisslinger

http://www.w3.org/2001/XMLSchema#string

Luca Malcovati

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

Michael Doubek

http://www.w3.org/2001/XMLSchema#string

Michael Steurer

http://www.w3.org/2001/XMLSchema#string

P2860

JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes.

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex

The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation

P304

245-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.22257

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Robert Kralovics

Paola Guglielmelli

Ashot S Harutyunyan

P577

2011-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51905107

http://www.w3.org/2001/XMLSchema#string

P698

22190018

http://www.w3.org/2001/XMLSchema#string

P921